Cochrane Database of Systematic Reviews 2009
DOI: 10.1002/14651858.cd007956
|View full text |Cite
|
Sign up to set email alerts
|

Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0
1

Year Published

2011
2011
2018
2018

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 12 publications
(7 citation statements)
references
References 54 publications
0
6
0
1
Order By: Relevance
“…Amifostine is a cytoprotective agent that showed initial success at attenuating salivary gland toxicity of 131 I therapy in preclinical and early clinical investigations (Bohuslavizki et al., ; Kutta et al., ). However, with unclear evidence of radioprotection in randomized controlled clinical trials (Kim et al., ; Ma, Xie, Chen, Wang, & Zuo, ; Ma, Xie, Jiang, Wang, & Zuo, ), additional studies are warranted to confirm or refute its benefits. Usefulness of salivary endoscopy (sialendoscopy) in relieving obstructive symptoms and improving salivary flow in 131 I‐induced sialadenitis was demonstrated in previous studies (Nahlieli & Nazarian, ; Strychowsky, Sommer, Gupta, Cohen, & Nahlieli, ).…”
Section: Treatment Of Salivary Gland Dysfunctionmentioning
confidence: 99%
“…Amifostine is a cytoprotective agent that showed initial success at attenuating salivary gland toxicity of 131 I therapy in preclinical and early clinical investigations (Bohuslavizki et al., ; Kutta et al., ). However, with unclear evidence of radioprotection in randomized controlled clinical trials (Kim et al., ; Ma, Xie, Chen, Wang, & Zuo, ; Ma, Xie, Jiang, Wang, & Zuo, ), additional studies are warranted to confirm or refute its benefits. Usefulness of salivary endoscopy (sialendoscopy) in relieving obstructive symptoms and improving salivary flow in 131 I‐induced sialadenitis was demonstrated in previous studies (Nahlieli & Nazarian, ; Strychowsky, Sommer, Gupta, Cohen, & Nahlieli, ).…”
Section: Treatment Of Salivary Gland Dysfunctionmentioning
confidence: 99%
“…Prevention of the 131 I sialadenitis and xerostomia may involve the use of agents that increase salivary flow and therefore minimize 131 I concentration in the saliva (Mandel & Mandel 2003). Recently, Ma et al (2009) reported that the use of amifostine has no significant radioprotective effects on salivary glands, although other studies suggest otherwise (Bohsulavizki et al 1998). In the relevant literature, there have been various recommended approaches to manage the different complications and include glandular massage (Mandel & Mandel 2003), sialogogic agents (LeVeque et al 1993, Wartofsky 2000, mouthwashes, good oral hygiene (Mandel & Mandel 2003) and hydration (Walter et al 2007).…”
Section: Lishedmentioning
confidence: 99%
“…Recently, Ma et al . () reported that the use of amifostine has no significant radioprotective effects on salivary glands, although other studies suggest otherwise (Bohsulavizki et al . ).…”
Section: Introductionmentioning
confidence: 98%
“…Doporučená dávka amifostinu činí 200 mg/m 2 tělesného povrchu. Aplikace se děje před podáním cytostatik či před ozářením v krátkodobé infuzi, během níž se doporučuje monitorovat krevní tlak, neboť může být spojena s přechodnou hypotenzí [2,17]. Dalšími vedlejšími účinky podávání amifostinu mohou být nauzea, průjmy, zvracení, somnolence, hypokalcemie, ale i Stevensův-Johnsonův syndrom a toxická epidermální nekrolýza [5,14,17].…”
Section: Amifostinunclassified